Agios signed an exclusive global licensing deal for Oscotec’s cevidoplenib, a next-generation SYK inhibitor being developed for immune thrombocytopenia (ITP), despite Oscotec’s Phase 2 failure to meet its primary platelet-count endpoint. Agios will pay $25 million upfront and could add up to $140 million in development and regulatory milestones across up to three indications. Cevidoplenib missed the primary goal of doubling platelet counts after 12 weeks, but Agios pointed to durable and clinically meaningful responses on secondary endpoints aligned with registrational ITP trial primary measures. Agios plans to move the program into Phase 3 in the first half of 2028 after additional CMC work. For biotech strategy, the transaction highlights a post-readout pivot pattern—using secondary signals to underwrite a larger clinical bet—while reflecting continued investor appetite for oral SYK inhibitors in hematology despite mixed early efficacy metrics.